Skip to content

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

BBOT

CIK 0001869105

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$137.35M
−80.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$2,143.55
+99.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$114.5M
Q1 May 2026
Cash
$52.66M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
80.11M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings